Immune signaling linked to cancer-drug heart inflammation
An observational study enrolled 236 patients in cancer-related heart care, including 88 taking immune checkpoint inhibitors, and identified an inflammation-linked signaling pathway.
Our read
Mechanisms- Studied:
- Preprint: cohort study of patients receiving immune checkpoint inhibitors, against patients without myocarditis
- What changed:
- Blood-cell JAK STAT signaling distinguished patients with heart inflammation from those without it
- The catch:
- Blood-cell signals were measured rather than signals within heart muscle
- In the record:
- The 292nd paper on clonal hematopoiesis of indeterminate potential with results in people; 665 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
The 236 patients enrolled in an observational study of cancer-related heart care included 88 taking immune checkpoint inhibitors, drugs that help the immune system attack cancer. Researchers used machine learning to analyze cytokines, immune-signaling proteins, in blood from patients taking these drugs.
Analyses of individual blood cells across three cohorts linked myocarditis, inflammation of the heart muscle, to JAK–STAT, a pathway that carries signals within cells. This pathway also ranked among those associated with myocarditis that resisted immune-suppressing drugs. The authors reported that JAK–STAT signaling was further amplified in people with clonal hematopoiesis of indeterminate potential, a condition in which groups of blood cells share acquired genetic changes.
Why it matters
Cancer care in later life raises questions about vulnerability to treatment-related heart inflammation. The authors proposed testing cytokine-guided risk assessment and treatments targeting JAK–STAT.
Caveats
The single-cell results came from blood and do not establish which signals were active within heart muscle. This preprint has not been peer-reviewed.
- Immune checkpoint inhibitors
- Inflammation
- JAK–STAT signaling
- Clonal hematopoiesis of indeterminate potential
- Immune checkpoint inhibitor myocarditis
- Humans
The paper
Yale School of Medicine
medRxiv, Nov 12, 2026, Open access, Preprint, not yet peer-reviewed
Comments
Be the first to comment.